|
| |
Protocol and Consent Forms
Last Updated: July 30, 2010
NOTE: Limited funding may be available to offset costs on certain protocols. Contact KCCOP for more information.
Brain/CNS
Also, see Cancer Control section for symptom
management/prevention trials.
Glioma
CTSU N0577: Protocol Summary |
Consent Form
ANAPLASTIC GLIOMA (oligodendroglioma, mixed,
or astrocytoma), post-surgical dx, Co-deleted 1p/19q, Central Path Review
required pre-regist; RT vs Temozolomide vs RT + concurrent & adjuv
Temozolomide (see Neurocognitive Certification & IMRT requirements in protocol)
RTOG 0837: Protocol Summary |
Consent Form
GLIOMA, Glioblastoma or Gliosarcoma (WHO grade IV), newly
dx; Central Path Review, Conventional chemoradiation + Adjuv
Temozolimide + Cediranib/placebo (see RT
credentialing requirements in protocol)
RTOG 0825 : Protocol Summary |
Consent Form
GLIOMA,
Glioblastoma or Gliosarcoma (Grade IV), newly dx; Central Path Review
!
Conventional Concurrent Chemoradiation + Adjuv Temozolomide + Bevacizumab/placebo
(double-blind) (See RT & Neurocognitive
Function Testing requirements in
protocol.)
RTOG 0627: Protocol Summary |
Consent Form
GLIOMA, glioblastoma multiforme or gliosarcoma,
recur, prior RT & Temozolomide required; Eval of Dasatinib
Meningioma
RTOG 0539: Protocol Summary |
Consent Form
MENINGIOMA,
WHO Grade I, II, or III, new dx or recur, any resection extent; Observation
for low-risk & RT for intermed- or high-risk groups (see RT credentialing
requirements in protocol)
TOP
Breast
Also, see
Cancer Control section for symptom
management/prevention trials.
Stage 0
CTSU PACCT-1: Protocol Summary |
Consent Form
Adj., Stgs 0, I , Selected II, Hormone+, N0, Candidate for cytotoxic + hormonal therapy; Trial of Individualized Options for Tx (TAILORx Trial)
NSABP B-39: Protocol Summary |
Consent Form
Adj., Stg. 0, I, II; Conventional Whole Breast RT vs Partial Breast RT (Multi-Catheter, Mammosite, or 3D-CRT)
(Sites need approval - check RT requirements in protocol.)
Stage I
CTSU PACCT-1: Protocol Summary |
Consent Form
Adj., Stgs 0, I , Selected II, Hormone+, N0, Candidate for cytotoxic + hormonal therapy; Trial of Individualized Options for Tx (TAILORx Trial)
IBCSG 25-02: Protocol Summary |
Consent Form
Adj., T1-3, N0-2, M0, Pre-meno, ER+ &/or PgR+; Triptorelin + TMX x 5 yr vs
Triptorelin + Exemestane x 5 yrs (both arms +/- adjuv chemo) (PARTICIPATION
LIMITED BY STUDY GROUP TO PRIOR ACCRUING SITES: SLCI & St. Joseph Oncology)
NSABP B-44-I:
Protocol Summary |
Pre-Randomization (HER2) Consent |
Treatment Consent Form
Adj., Stgs I-III, HER2(+), Node(+) or High Risk Node(-);
Taxol + Carboplatin + Trastuzumab
!
Trastuzumab +/- Bevacizumab (INDUSTRY TRIAL - WILL RECEIVE FUNDS, NOT
CREDITS. PARTICIPATION LIMITED - ONLY SLH-KC CURRENTLY APPROVED.)
NSABP B-46-I:
Protocol Summary |
Consent Form
Adj., Stgs I-IIIC (no IIIB), Node(+) or High-risk
Node(-), HER2(-); Docetaxel + Doxorubicin + Cyclophosphamide vs Docetaxel +
Cyclophosphamide vs Docetaxel + Cyclophosphamide + Bevacizumab (Industry
trial – will receive funds, not credits. participation limited.)
CALGB 40101: Protocol Summary |
Consent Form
Adj., T1‑4, N0-3, M0; Cyclophosphamide + Doxorubicin vs Paclitaxel
SWOG S0221: Protocol Summary |
Consent Form
Adj., Stg I, II, III, Node+ or Hi-Risk
Node -, male pts allowed; Continuous Schedule Doxorubicin+Cyclophosphade+GCSF vs q2wk Doxorubicin+Cyclophosphade,
both ! Taxol
(q2wks vs weekly x 12 wks)
NSABP B-39: Protocol Summary |
Consent Form
Adj., Stg. 0, I, II; Conventional Whole Breast RT vs Partial Breast RT (Multi-Catheter, Mammosite, or 3D-CRT)
(Sites need approval - check RT requirements in protocol.)
CTSU N063D (ALTTO): Protocol Summary |
Consent Form
(Neo-)Adj., known ER/PgR or ER,
HER2+, must have plans for concurrent non-anthracycline platinum chemo; Eval of sequences of Lapatinib &/or
Trastuzumab (only Design 2B still open)
Stage II
CTSU PACCT-1: Protocol Summary |
Consent Form
Adj., Stgs 0, I , Selected II, Hormone+, N0, Candidate for cytotoxic + hormonal therapy; Trial of Individualized Options for Tx (TAILORx Trial)
IBCSG 25-02: Protocol Summary |
Consent Form
Adj., T1-3, N0-2, M0, Pre-meno, ER+ &/or PgR+; Triptorelin + TMX x 5 yr vs
Triptorelin + Exemestane x 5 yrs (both arms +/- adjuv chemo) (PARTICIPATION
LIMITED BY STUDY GROUP TO PRIOR ACCRUING SITES: SLCI & St. Joseph Oncology)
NSABP B-44-I:
Protocol Summary |
Pre-Randomization (HER2) Consent |
Treatment Consent Form
Adj., Stgs I-III, HER2(+), Node(+) or High Risk Node(-);
Taxol + Carboplatin + Trastuzumab
!
Trastuzumab +/- Bevacizumab (INDUSTRY TRIAL - WILL RECEIVE FUNDS, NOT
CREDITS. PARTICIPATION LIMITED - ONLY SLH-KC CURRENTLY APPROVED.)
NSABP B-46-I:
Protocol Summary |
Consent Form
Adj., Stgs I-IIIC (no IIIB), Node(+) or High-risk
Node(-), HER2(-); Docetaxel + Doxorubicin + Cyclophosphamide vs Docetaxel +
Cyclophosphamide vs Docetaxel + Cyclophosphamide + Bevacizumab (Industry
trial – will receive funds, not credits. participation limited.)
ACOSOG Z1071:
Protocol Summary |
Consent Form
Surg, T0-4, N1-2,
M0; Eval of SLN & ALND following neo-adjuv therapy
CALGB 40603:
Protocol Summary |
Consent Form
Neoadj., Stg II-IIIA, Hormone-Receptor Poor/HER2-,
resectable; Carboplatin +/- Bevacizumab + weekly Paclitaxel ! Dose-Dense AC
CTSU N063D (ALTTO):
Protocol Summary |
Consent Form
(Neo-)Adj., known ER/PgR or ER,
HER2+, must have plans for concurrent non-anthracycline platinum chemo; Eval of sequences of Lapatinib &/or
Trastuzumab (only Design 2B still open)
ACOSOG Z1031:
Protocol Summary |
Consent Form |
Supplemental Sample Consent |
Optional Genome Research Consent
Neoadj., T2-4c, any N, M0, Post-meno, ER+; 16-18 wks Exemestane vs Letrozole
vs Anastrozole!Bx !
Continued AI therapy, chemo, or surg (depending on Ki67 score)
NSABP B-41: Protocol Summary |
Consent Form
Neoadj., Stgs IIA-B & selected Stg IIIA, HER2+, palpable & operable; AC
! Taxol +
Trastuzumab vs AC
! Taxol + Lapatinib vs
AC
! Taxol + Trastuzumab + Lapatinib
(all Arms followed by Surg & post-surg Trastuzumab, & required correlative
studies for path CR) (INDUSTRY TRIAL - WILL RECEIVE FUNDS, NOT CREDITS.
PARTICIPATION LIMITED - ONLY SLH-KC CURRENTLY APPROVED.)
SWOG S0221: Protocol Summary |
Consent Form
Adj., Stg I, II, III, Node+ or Hi-Risk
Node -, male pts allowed; Continuous Schedule Doxorubicin+Cyclophosphade+GCSF vs q2wk Doxorubicin+Cyclophosphade,
both ! Taxol
(q2wks vs weekly x 12 wks)
NSABP B-39: Protocol Summary |
Consent Form
Adj., Stg. 0, I, II; Conventional Whole Breast RT vs Partial Breast RT (Multi-Catheter, Mammosite, or 3D-CRT)
(Sites need approval - check RT requirements in protocol.)
CALGB 40101: Protocol Summary |
Consent Form
Adj., T1‑4, N0-3, M0; Cyclophosphamide + Doxorubicin vs Paclitaxel
Stage III
CALGB 40101: Protocol Summary |
Consent Form
Adj., T1‑4, N0-3, M0; Cyclophosphamide + Doxorubicin vs Paclitaxel
NSABP B-44-I:
Protocol Summary |
Pre-Randomization (HER2) Consent |
Treatment Consent Form
Adj., Stgs I-III, HER2(+), Node(+) or High Risk Node(-);
Taxol + Carboplatin + Trastuzumab
!
Trastuzumab +/- Bevacizumab (INDUSTRY TRIAL - WILL RECEIVE FUNDS, NOT
CREDITS. PARTICIPATION LIMITED - ONLY SLH-KC CURRENTLY APPROVED.)
CALGB 40502: Protocol Summary |
Consent Form
Stg IIIC or IV, known HER-2/neu, ER, & PgR status; 1st-line randomized trial of
Paclitaxel vs Nanoparticle Albumin-Bound Paclitaxel + Bevacizumab vs
Ixabepilone + Bevacixumab (all given weekly)
NSABP B-46-I:
Protocol Summary |
Consent Form
Adj., Stgs I-IIIC (no IIIB), Node(+) or High-risk
Node(-), HER2(-); Docetaxel + Doxorubicin + Cyclophosphamide vs Docetaxel +
Cyclophosphamide vs Docetaxel + Cyclophosphamide + Bevacizumab (Industry
trial – will receive funds, not credits. participation limited.)
ACOSOG Z1071:
Protocol Summary |
Consent Form
Surg, T0-4, N1-2,
M0; Eval of SLN & ALND following neo-adjuv therapy
SWOG S0221: Protocol Summary |
Consent Form
Adj., Stg I, II, III, Node+ or Hi-Risk
Node -, male pts allowed; Continuous Schedule Doxorubicin+Cyclophosphade+GCSF vs q2wk Doxorubicin+Cyclophosphade,
both ! Taxol
(q2wks vs weekly x 12 wks)
CALGB 40603:
Protocol Summary |
Consent Form
Neoadj., Stg II-IIIA, Hormone-Receptor Poor/HER2-,
resectable; Carboplatin +/- Bevacizumab + weekly Paclitaxel ! Dose-Dense AC
CTSU N063D (ALTTO): Protocol Summary |
Consent Form
(Neo-)Adj., known ER/PgR or ER,
HER2+, must have plans for concurrent non-anthracycline platinum chemo; Eval of sequences of Lapatinib &/or
Trastuzumab (only Design 2B still open)
ACOSOG Z1031:
Protocol Summary |
Consent Form |
Supplemental Sample Consent |
Optional Genome Research Consent
Neoadj., T2-4c, any N, M0, Post-meno, ER+; 16-18 wks Exemestane vs Letrozole
vs Anastrozole!Bx !
Continued AI therapy, chemo, or surg (depending on Ki67 score)
NSABP B-41: Protocol Summary |
Consent Form
Neoadj., Stgs IIA-B & selected Stg IIIA, HER2+, palpable & operable; AC
! Taxol +
Trastuzumab vs AC
! Taxol + Lapatinib vs
AC
! Taxol + Trastuzumab + Lapatinib
(all Arms followed by Surg & post-surg Trastuzumab, & required correlative
studies for path CR) (INDUSTRY TRIAL - WILL RECEIVE FUNDS, NOT CREDITS.
PARTICIPATION LIMITED - ONLY SLH-KC CURRENTLY APPROVED.)
Metastatic / Recurrent
CALGB 40502: Protocol Summary |
Consent Form
Stg IIIC or IV, known HER-2/neu, ER, & PgR status; 1st-line randomized trial of
Paclitaxel vs Nanoparticle Albumin-Bound Paclitaxel + Bevacizumab vs
Ixabepilone + Bevacixumab (all given weekly)
TOP
Cancer Control
Cancer Control: Any Site
SWOG S0702:
Protocol Summary |
Consent Form
Bone Mets
from any site, plan to receive Zoledronic acid; Observational study of ONJ
MDA 2007-0791:
Protocol Summary |
Consent Form
Any site, self-reported pain (any cause), prescribed or
using Morphine or Oxycodone SR; Oral Methadone vs switching between Morphine
SR & Oxycodone SR (see protocol for Methadone prescriber training
requirement)
URCC U1105: Protocol Summary |
Consent Form
Any cancer dx, no prior chemo, planned Cisplatin, Carboplatin, Oxaliplatin,
Doxorubicin, or Epirubicin-containing regimen w/o concurrent RT or IFN; 4 Double-blind regimens for
preventing delayed nausea
URCC 08106: Protocol Summary |
Consent Form
Any cancer dx (no leukemia), M0, chemo naive, planning to start chemo lasting >6
wks (tx cycles can be 2, 3, or 4 wks); Effects of exercise on cancer-related
fatigue (staff administering exercise intervention must be trained &
approved by URCC)
Cancer Control: Breast
NSABP B-43-CC:
Protocol Summary |
Pre-Entry HER2 Test Consent Form |
Consent Form
Adj., Stg 0 (DCIS
or mixed DCIS/LCIS), post-lumpectomy, HER2+; RT +/- concurrent Trastuzumab
CALGB 70501: Protocol Summary |
Consent Form
Companion Study to
CALGB 30607, 40502,
70604,
80405, + others to be opened in future; Symptom & Perf Status
self-reporting via Internet (dedicated CRA for this study must be
available; laptop will be provided; CRA must complete training by KCCOP)
RTOG 0517: Protocol Summary |
Consent Form
BONE METS (from Breast, Lung, Prostate), must complete EBRT <14 days pre-regist, chemo or hormonal
therapy allowed; Zometa+Vit D+Ca +/- Single Dose Sr-89 or Sm-153
CALGB 70301: Protocol Summary |
Consent Form
Companion Study to CALGB 40101; QOL, Employment & Informal Care Cost Analysis
CALGB 70604: Protocol Summary |
Consent Form
BONE METS (from Breast, Prostate, Mult Myeloma), no prior
IV bisphosphonates or radiopharmaceuticals; Standard vs Longer Dosing Interval
of Zoledronic Acid
Cancer Control: GI
NSABP P-5: Protocol Summary |
Consent Form
COLON, resected adenocarcinoma, Stg I or II, post-adjuv
therapy; Rosuvastatin vs placebo polyp prevention trial
CALGB 70501: Protocol Summary |
Consent Form
Companion Study to
CALGB 30607,
40502,
70604,
80405, + others to be opened in future; Symptom & Perf Status
self-reporting via Internet (dedicated CRA for this study must be
available; laptop will be provided; CRA must complete training by KCCOP)
MDA 2008-0005: Protocol Summary |
Consent Form
COLORECTAL, Mets, scheduled to receive
Irinotecan alone or w/5-FU, Cetuximab, or other biologics; CASAD vs placebo
for diarrhea tx/prevention (PARTICIPATION CURRENTLY LIMITED TO SLCI &
RMC)
Cancer Control: GU
RTOG 0517: Protocol Summary |
Consent Form
BONE METS (from Breast, Lung, Prostate), must complete EBRT <14 days pre-regist, chemo or hormonal
therapy allowed; Zometa+Vit D+Ca +/- Single Dose Sr-89 or Sm-153
CALGB 70604: Protocol Summary |
Consent Form
BONE METS (from Breast, Prostate, Mult Myeloma), no prior
IV bisphosphonates or radiopharmaceuticals; Standard vs Longer Dosing Interval
of Zoledronic Acid
Cancer Control: Gyn
GOG-0237: Protocol Summary |
Consent Form
CERVICAL, Atypical glandular cells; Analysis
of CA-IX, p16, proliferative markers, & HPV in diagnosing cervical lesions
GOG-0259: Protocol Summary |
Consent Form
OVARIAN, FALLOPIAN TUBE, or PRIM PERITONEAL,
Recur or Persis, active disease or tx not required; Nurse-Delivered WRITE
Symptoms vs Self-Directed WRITE Symptoms vs Care as Usual
Cancer Control: Lung
RTOG 0517: Protocol Summary |
Consent Form
BONE METS (from Breast, Lung, Prostate), must complete EBRT <14 days pre-regist, chemo or hormonal
therapy allowed; Zometa+Vit D+Ca +/- Single Dose Sr-89 or Sm-153
CALGB 70501: Protocol Summary |
Consent Form
Companion Study to
CALGB 30607,
40502,
70604,
80405, + others to be opened in future; Symptom & Perf Status
self-reporting via Internet (dedicated CRA for this study must be
available; laptop will be provided; CRA must complete training by KCCOP)
SWOG S0424: Protocol Summary |
Consent Form
Molecular Epidemiology Study; NSCLC in Smoking &
Non-Smoking Men/Women
Cancer Control: Lymphoma
SWOG 8819: Protocol Summary
(no consent form)
Path Companion to SWOG-coordinated protocols for prev untreated, NH
lymphoma
Cancer Control: Myeloma
CALGB 70604: Protocol Summary |
Consent Form
BONE METS (from Breast, Prostate, Mult Myeloma), no prior
IV bisphosphonates or radiopharmaceuticals; Standard vs Longer Dosing Interval
of Zoledronic Acid
TOP
GI
Also, see
Cancer Control section for symptom
management/prevention trials.
Colon
CALGB 80702:
Protocol Summary |
Consent Form
COLON, Stg III, resected; 6 vs 12 txs of adjuv FOLFOX +
Celecoxib/placebo
Colorectal
CALGB 80405:
Protocol Summary |
Consent Form
COLORECTAL, Adenocarcinoma (Adv or Mets), Untreated, Wild type
K-ras (determined pre-regist ); Either FOLFOX or FOLFIRI with either Bevacizumab or Cetuximab
Gallbladder
SWOG S0941:
Protocol Summary |
Consent Form
GALLBLADDER or CHOLANGIOCARCINOMA, locally adv (unresectable)
or mets; Sorafenib + Erlotinib
Liver
CALGB 80802:
Protocol Summary |
Consent Form
HEPATOCELLULAR, locally adv or mets, no prior allografts;
Doxorubicin +/- Sorafenib
CTSU E1208:
Protocol Summary |
Consent Form
HEPATOCELLULAR (limited to liver), unresectable;
Chemoemobilization +/- Sorafenib
Pancreas
SWOG S0727 :
Protocol Summary |
Consent Form
PANCREAS, Stg IV, Unresec, adenocarcinoma; Gemcitabine +
Erlotinib +/- IMC-A12 as 1st line tx
Rectal
NSABP R-04: Protocol Summary |
Consent Form
RECTAL, Stgs II-III, operable invasive adenocarcinoma; Pre-op RT + Capecitabine +/- Oxal vs Pre-op RT + CI 5-FU +/- Oxal
Other
SWOG S0941:
Protocol Summary |
Consent Form
GALLBLADDER or CHOLANGIOCARCINOMA, locally adv (unresectable)
or mets; Sorafenib + Erlotinib
TOP
GU
Also, see
Cancer Control section for symptom
management/prevention trials.
Prostate: Stage II
RTOG 0534: Protocol Summary |
Consent Form
PROSTATE, Adenocarcinoma, T3N0/Nx or T2N0/Nx +/- positive
surg margin, rising PSA post-radical prostatectomy; Prostate Bed RT (PBRT) vs
PBRT + Neoadjuv & Concurrent short-term androgen depriv (NC-STAD) vs PBRT +
NC-STAD + Pelvic Lymph Node RT (see RT & neurocognitive function
credentialing requirements in protocol)
RTOG 0232: Protocol Summary |
Consent Form
PROSTATE, T1c-2b, Nx/N0, M0; Ext Beam RT+Transperineal
Interstitial Permanent Brachytherapy vs Brachytherapy alone (Sites need approval - check RT requirements in protocol.)
RTOG 0815: Protocol Summary |
Consent Form
PROSTATE, Adenocarcinoma, Interm risk (Gleason 7, PSA>10
& <20, &/or Clin Stg T2b-T2c); Dose-Escal RT +/- Short-Term Androgen
Deprivation (see RT credentialing requirements in protocol)
Prostate: Stage III
RTOG 0534: Protocol Summary |
Consent Form
PROSTATE, Adenocarcinoma, T3N0/Nx or T2N0/Nx +/- positive
surg margin, rising PSA post-radical prostatectomy; Prostate Bed RT (PBRT) vs
PBRT + Neoadjuv & Concurrent short-term androgen depriv (NC-STAD) vs PBRT +
NC-STAD + Pelvic Lymph Node RT (see RT & neurocognitive function
credentialing requirements in protocol)
Prostate: Stage IV
MDA ID-00156 :
Protocol Summary |
Consent Form
PROSTATE,
Adenocarcinoma, Stg IV, Androgen-Indep; Induction Chemo ! Doxorubicin +/-
single dose
Strontium-89
Renal
CTSU E2804:
Protocol Summary |
Consent Form
RENAL, clear cell w/<25% any other histology, mets untreatable by RT or
surg, prior nephrectomy (some exceptions); VEGF, RAF Kinase, & MTOR Comb.
Targeted Therapy w/Bevacizumab, Sorafenib, & Temsirolimus
CTSU
E2805:
Protocol Summary |
Consent Form
RENAL, Resectable, no distant mets; Double-blind adjuv Sunitinib vs Sorafenib vs
placebo
Urinary Tract
CALGB 90601: Protocol Summary |
Consent Form
URINARY TRACT (Renal Pelvis, Ureter, Bladder, Prostate, or
Urethra), Transitional cell, Mets or Locally Adv; Gemcitabine + Cisplatin +
Bevacizumab/placebo
TOP
GYN
Also, see
Cancer Control section for symptom
management/prevention trials.
Endometrial
GOG-0248:
Protocol Summary |
Consent Form
ENDOMETRIAL, Stg III-IV, persis, or recur, likely
incurable by surg or RT; Eval of Temsirolimus
RTOG 0921:
Protocol Summary |
Consent Form
ENDOMETRIAL, post-hysterectomy for uterine ca & post-BSO,
Stgs IC, IIA-B, III, & IVA; IMRT + concurrent Cisplatin & Bevacizumab
à Carboplatin + Paclitaxel (see
RT credentialing requirements in protocol)
GOG-0249:
Protocol Summary |
Consent Form
ENDOMETRIAL, Post-Hyst/BSO
& peritoneal cytol, Stg I-IIA (high-interm risk), IIB (occult, any histol, +/-
risk factors), I-IIB (occult, serous or clear, +/- risk factors); Pelvic RT vs
Vaginal Cuff Brachy + Paclitaxel & Carboplatin
Ovarian
GOG-0126T: Protocol Summary |
Consent Form
OVARIAN or FALLOPIAN TUBE (Recur or Persis) or PERITONEAL
(Prim), platinum-resistant or -refractory; Belinostat + Carboplatin
GOG 0212: Protocol Summary |
Consent Form
OVARIAN or FALLOPIAN TUBE (Adv, Epith) or PERITONEAL (Prim), CR after Prim Platinum/Taxane chemo; Maint Chemo (12 monthly cycles of Paclitaxel
or CT-2103) vs No Tx until relapse (PARTICIPATION LIMITED)
TOP
Leukemia
Also, see Cancer Control section for symptom
management/prevention trials.
Acute
SWOG E1905:
Protocol Summary |
Consent Form
MDS, CMMoL (Dysplatic), or AML (Multilineage Dysplasia);
Azacitidine +/- Etinostat
Chronic
CALGB 10404:
Protocol Summary |
Consent Form
CLL (B-cell), symptomatic & active intermediate or
high-risk Rai staging, no prior tx; Randomized study of 4 Fludarabine/Antibody
Combinations
SWOG E1905:
Protocol Summary |
Consent Form
MDS, CMMoL (Dysplatic), or AML (Multilineage Dysplasia);
Azacitidine +/- Etinostat
CTSU E2905:
Protocol Summary |
Consent Form
MDS or non-proliferative CMML, Low- or Intermediate-1-risk, symptomatic
anemia; Frequency of Major Erythroid Response to Lenalidomide +/- Epoetin Alfa
Ancillary
SWOG 9007: Protocol Summary |
Consent Form
MANDATORY Cytometry Companion to all Leukemia tx protocols
SWOG S9910: Protocol Summary |
Consent Form
Ancillary; specimen submission to Centralized Reference Lab & Tissue Repository
CALGB 8461: Protocol Summary |
Consent Form
Cytogenetics study for prev untreated AML, ALL, MDS
CALGB 9665: Protocol Summary |
Consent Form
Tissue Bank for prev untreated leukemia pts (acute or chronic) & MDS
CALGB 9760: Protocol Summary |
Consent Form
Multidrug Resistance studies for prev untreated AML & ALL
TOP
LungAlso, see
Cancer Control section for symptom
management/prevention trials.
NSC: Stage I
CALGB 140503:
Protocol Summary |
Consent Form
NSC,
peripheral nodule <2cm, N0, M0; Lobectomy vs Sublobar Resection (if
pt is randomized to Lobectomy arm & surgeon plans to use VATS procedure,
surgeon must be credentialed per protocol)
RTOG 0915: Protocol Summary |
Consent Form
NSC, Stgs IA-IB, no bronchioalveolar cell, medically
inoperable; Eval of 2 SBRT schedules (see RT credentialing requirements in
protocol)
CTSU E1505:
Protocol Summary |
Consent Form
NSC, Stgs IB (>4cm) - IIIA, completely resected; 1 of 4 chemo
regimens +/- Bevacizumab
RTOG 0813:
Protocol Summary |
Consent Form
NSC, Stg I, centrally located, medically inoperable; Eval
of Stereotactic Lung RT (see RT credentialing requirements in protocol)
NSC: Stage II
CTSU E1505:
Protocol Summary |
Consent Form
NSC, Stgs IB (>4cm) - IIIA, completely resected; 1 of 4 chemo
regimens +/- Bevacizumab
NSC: Stage IIIA
CTSU E1505:
Protocol Summary |
Consent Form
NSC, Stgs IB (>4cm) - IIIA, completely resected; 1 of 4 chemo
regimens +/- Bevacizumab
CALGB 30605:
Protocol Summary |
Consent Form
NSC, Stgs IIIA-B (Unresectable), no prior
chemo or RT for NSC; Induction Chemo
! Thoracic RT + Erlotinib
RTOG 0617:
Protocol Summary |
Consent Form
NSC, Stgs IIIA-B (Unresectable), M0; Stand Dose (60Gy) vs High-Dose (74Gy)
Conformal RT + Concurrent & Consolidation Carbo/Taxol +/- Cetuximab (Sites
need approval – check RT requirements in protocol)
NSC: Stage IIIB
CALGB 30605:
Protocol Summary |
Consent Form
NSC, Stgs IIIA-B (Unresectable), no prior
chemo or RT for NSC; Induction Chemo
! Thoracic RT + Erlotinib
CALGB 30607:
Protocol Summary |
Consent Form
NSC, Stg IIIB-IV, must have rcvd 4 cycles of
platinum-based chemo +/- Bevacizumab & had
no progression; Sunitinib vs placebo
RTOG 0617:
Protocol Summary |
Consent Form
NSC, Stgs IIIA-B (Unresectable), M0; Stand Dose (60Gy) vs High-Dose (74Gy)
Conformal RT + Concurrent & Consolidation Carbo/Taxol +/- Cetuximab (Sites
need approval – check RT requirements in protocol)
NSC: Stage IV
CALGB 30607:
Protocol Summary |
Consent Form
NSC, Stg IIIB-IV, must have rcvd 4 cycles of
platinum-based chemo +/- Bevacizumab & had
no progression; Sunitinib vs placebo
SWOG S0819:
Protocol Summary |
Consent Form
NSC, Stg IV, new dx or recur; Carboplatin/Paclitaxel vs
Carboplatin/Paclitaxel/Bevacizumab +/- Concurrent Cetuximab
TOP
Lymphoma
Also, see
Cancer Control section for symptom
management/prevention trials.
Non-Hodgkin's
CALGB 50401: Protocol Summary |
Consent Form
NH, Not Rituximab-refractory, Grade 1, 2, or 3a,
Follicular; Lenalidomide vs Rituximab + Lenalidomide
Ancillary
SWOG 8947: Protocol Summary |
Consent Form
Serum Companion to SWOG-coord protocols for prev
untreated, NH lymphoma
TOP
Melanoma
Also, see
Cancer Control section for symptom
management/prevention trials.
CTSU E1697:
Protocol Summary |
Consent Form
Stg T2b N0, T3a-b N0, T4a-b N0, or T1-4 N1a-2a (micro), cutaneous, post-wide
excision +/- lymphadenectomy; High-Dose IFN-α2b
(x 4 wks)
SWOG S0826:
Protocol Summary |
Consent Form
Stg IV, cutaneous or mucosal origin, Eval
of SCH 727965
Myeloma
Also, see
Cancer Control section for symptom
management/prevention trials.
SWOG S0777: Protocol Summary |
Consent Form
MM, no prior tx, no intent for immed Autologous Stem Cell
Transplant; Lenalidomide + Low Dose Dexamethasone +/- Bortezomib for Induction
SWOG S0120: Protocol Summary |
Consent Form
MGUS, asymptomatic Myeloma, or Solitary Plasmacytoma, not requiring tx;
Observational Biologic Study (BM aspir & Perip Blood)
TOP
|
